Monday, November 30, 2015

Pharma, antipsychotic drugs and the Book of Woe

Gary Greenberg wrote "Book of Woe: The DSM and the Unmaking of Psychiatry."

Pharma, antipsychotic drugs and the Book of Woe


Inquirer colleague Tirdad Derakhshani wrote the other day (link here) about Connecticut therapist and science writer Gary Greenberg, who is a critic of trends in psychiatry and the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders. The fifth edition is just out. So is Greenberg's book, "The Book of Woe: The DSM and the Unmaking of Psychiatry" (Blue Rider Press, $28.95).

(You will need to use a promo code (Q36W) to access

Greenberg writes about the efforts to add clear scientific measures to mental health care, in part because it helps drug companies sell more medicine because insurers, public or private, can base reimbursement on something. Greenberg's web site is here.

That has partly led to an explosion of use for antipsychotic drugs that were originally only approved for conditions such as schizophrenia, which has a small - and thus less profitable - population group.

But pharma likes measure only to a point. The vague and shifting definitions of mental health conditions allow doctors even greater latitude to prescribe medicine off-label in hopes that it makes their patient happier. And drug companies do all they can to encourage such prescribing.

Many of the largest financial penalties paid by drug companies followed federal investigations that looked at drugmakers' marketing practices related to antipsychotic and depression medicines.

The big one still pending relates to Johnson & Johnson's marketing practices around the antipsychotic Risperdal. J&J has mentioned the investigation in SEC filings and reports suggest the penalties could exceed $2 billion. There are also state and local suits related to marketing and safety of that drug. A Wednesday Inquirer story deals with a slice of that. A link is here.


Inquirer Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Inquirer Staff Writer
Also on
letter icon Newsletter